Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction. Results of the CHARM low-left ventricular ejection fraction trials

Abstract

Heart failure, ventricles, aldosterone antagonists, angiotensin-converting enzyme inhibitors